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Caveolin-1 (Cav-1) is a scaffolding protein important for regulating receptor signaling cascades by partitioning signaling
molecules into membrane microdomains. Disruption of the CAV1 gene has recently been identiﬁed as a rare structural variant
associated with schizophrenia. Although Cav-1 knockout (KO) mice displayed no baseline behavioral disruptions, Cav-1 KO
mice, similar to schizophrenic individuals, exhibited increasedsensitivity to the psychotomimetic N-methyl-D-aspartate receptor
antagonist phencyclidine (PCP). Thus, PCP disruption of prepulse inhibition (PPI) and PCP-induced mouse locomotor activity
were both enhanced by genetic deletion of Cav-1. Interestingly, genetic deletion of Cav-1 rendered the atypical antipsychotics
clozapine and olanzapine and the 5-HT2A-selectiveantagonistM100907ineffective atnormalizing PCP-induced disruptionof PPI.
We also discovered that genetic deletionof Cav-1 attenuated 5-HT2A-induced c-Fos and egr-1 expression in mouse frontal cortex
and also reduced 5-HT2A-mediated Ca
2þ mobilization in primary cortical neuronal cultures. The behavioral effects of the 5-HT2A
agonist (2,5-dimethoxy-4-iodoamphetamine) including head twitch responses and disruption of PPI were also attenuated by
genetic deletion of Cav-1, indicating that Cav-1 is required for both inverse agonist (that is, atypical antipsychotic drug) and
agonist actions at 5-HT2A receptors. This study demonstrates that disruption of the CAV1 gene—a rare structural variant
associated with schizophrenia—is not only pro-psychotic but also attenuates atypical antipsychotic drug actions.
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Introduction
Schizophrenia—affecting 1% of the world’s population—is a
genetically heterogeneous disease with devastating conse-
quences to affected individuals.
1–4 It now appears that
schizophrenia is due to both common and rare gene
mutations as well as copy-number variations. The identiﬁca-
tion and study of exceedingly rare mutations such as DISC1
has had a major impact on our understanding of the potential
genetic underpinnings of psychiatric disease.
5,6 Recent
analyses of genomic structural variations in individuals with
schizophrenia indicated that the gene caveolin-1 (CAV1)i s
disruptedbyaninsertional mutation,therebyidentifyingCAV1
as a rare structural variant associated with schizophrenia.
7
The CAV1, -2 and -3 genes encode caveolins, which
represent a family of multi-functional scaffolding proteins
and cholesterol-binding proteins that mediate cholesterol
trafﬁcking to lipid microdomains at the plasma membrane.
8
Caveolins also function as protein scaffolds to organize
proteins and lipids together in membrane domains and
thereby control various cellular functions including vesicular
trafﬁcking, lipid homeostasis and signal transduction.
9,10
Cav-1 and Cav-2 are widely expressed in the central
and peripheral nervous systems mainly in cortical and
hippocampal neurons as well as brain microvessels, astro-
cytes, oligodendrocytes, Schwann cells and dorsal root
ganglia cells
10–12 while Cav-3 is muscle-speciﬁc. Transcrip-
tional proﬁling studiesof mRNAsdemonstrate thatboth Cav-1
and Cav-2 are expressed in relevant central nervous system
cells including layer III and V pyramidal cortical neurons.
13
The relevant functional role(s) of Cav-1 vis-a-vis the
pathogenesis of schizophrenia is undeﬁned. As many G
protein-coupled neurotransmitter receptors, heterotrimeric G
proteins and signaling effectors are known Cav-1 interacting
partners,
10,11,14 disruption of CAV1 will likely impair neuronal
signaling thereby leading to symptoms of schizophrenia in
susceptible individuals. Targeted disruption of the CAV1 gene
in mice provides a knockout (KO) animal model, which
recapitulates the life-long disruption of CAV1 seen as a rare
structural variant associated with schizophrenia. Here, we
report that genetic deletion of Cav-1 in mice induces a
propsychotic-like condition whereby mice are supersensitive
to the psychotomimetic actions of the N-methyl-D-aspartate
(NMDA)-receptor antagonist phencyclidine (PCP). Further-
more, Cav-1 KO mice are also resistant to the actions of
atypical antipsychotic drugs andselected serotonergic agents
implying an underlying disruption of serotonergic signaling
also ispresent.TheseﬁndingssuggestthedisruptioninCAV1
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responsiveness to atypical antipsychotics because of intrinsic
alterations in serotonergic signaling.
Materials and methods
See Supplementary Information for additional materials and
methods.
In vivo studies in mice. All experiments were approved by
the Institutional Animal Care and Use Committees at the
University of North Carolina, Chapel Hill, NC, USA. Cav-1 KO
mice were obtained from the Jackson Laboratories (Bar
Harbor, ME, USA) and were housed under standard
conditions—12-h light–dark cycle with food and water
provided ad libitum. Adult, age-matched (10–15 week) male
and female littermate wild-type and Cav-1 KO drug-naive
mice were used for all behavioral testing.
Prepulse inhibition. Prepulse inhibition (PPI) testing and
analysis was performed as described previously.
15,16 Adult
male and female littermate wild-type and Cav-1 KO mice
were pre-administered (10mlkg
 1, intraperitoneally (i.p.))
vehicle (0.9% saline; 50mM tartaric acid), clozapine (0.5,
1.0mgkg
 1), olanzapine (0.5mgkg
 1) or M100907 (0.5,
1.0mgkg
 1) and returned to their home cage. After 30min,
animals were administered phencyclindine (2.0, 4.0 or
6mgkg
 1, i.p.) and immediately placed into the PPI
apparatus (SR-LAB Startle Response System, San Diego
Instruments, San Diego, CA, USA). The auditory pulse
protocol, test trials used and PPI calculation have been
reported previously.
15,16 The data were analyzed with SR-
LAB programs and are presented as means±s.e.m. The
calculated PPI values from all groups were analyzed using a
one-way analysis of variance followed by Newman–Keuls
multiple comparison test with Graphpad Prism 5.0
(Graphpad Software Inc., La Jolla, CA, USA). In all cases,
Po0.05 was considered statistically signiﬁcant.
Open ﬁeld activity. Locomotor activity was assessed under
standardized environmental conditions in 25.8 25.8cm
Plexiglas chambers with photo-beams spaced at 1.52cm
(AccuScan Instruments, Columbus, OH, USA) as previously
described.
15,16 For dose responses to PCP, mice were placed
into the open ﬁeld and 30min later, PCP (2.0, 4.0 6.0mgkg
 1)
was administered and animals were immediately returned to
the open ﬁeld for 90min. For antipsychotic studies, mice were
injected (i.p.) with vehicle (0.9% saline, 50mM tartaric acid),
clozapine (1.0mgkg
 1), M100907 (0.1, 1.0mgkg
 1)o r
haloperidol (0.1mgkg
 1) and placed into the open ﬁeld. After
30min, PCP (6.0mgkg
 1) was administered and mice were
immediately returned to the open ﬁeld for 90min. Activity
was monitored throughout this entire period. Horizontal activity
was measured as the total distance traveled in centimeters.
Stereotypy counts reported correspond to the number of times
that stereotypic behavior was observed in the animal. A break
in stereotypy of 1s or more was required to separate one
stereotypic episode from the next. If the animal breaks the
same beam (or set of beams) repeatedly, the monitor considers
that the animal is exhibiting stereotypy and each event is
counted. The means±s.e.m. of the locomotor responses and
stereotypy counts were analyzed using Graphpad Prism 5.0.
Cumulative responses were analyzed using a one-way analysis
of variance followed by Newman–Keuls multiple comparison
test and statistical signiﬁcant was set at Po0.05.
DOI-induced head twitch. Wild-type (WT) and Cav-1 KO
littermate mice were injected i.p. with saline, or 0.25
to 1.25mgkg
 1 of DOI (2,5-dimethoxy-4-iodoamphetamine).
The number of head twitches was counted and recorded
in 5min bins for a 35-min period immediately after injection.
A subset of the 1.0 and 1.25mgkg
 1 injections were counted
by two observers, one of whom was blinded to the geno-
type; similar results were obtained by both observers (data
not shown). All the other head twitch experiments were
performed by one blinded observer. The means±s.e.m.
of the head twitch responses were analyzed using Graphpad
Prism 5.0 and statistical differences analyzed using a
one-way analysis of variance followed by Newman–Keuls
multiple comparison test and statistical signiﬁcant was set
at Po0.05.
Quantitative reverse transcriptase-PCR for c-FOS and
egr-1 mRNA expression. WT and Cav-1 KO littermates
were injected with the 5-HT2-selective agonist DOI
(1.0mgkg
 1, i.p.) and after 1h, mice were euthanized, and
total RNA was immediately isolated from micro-dissected
frontal cortex tissue using Trizol (Invitrogen, Carlsbad, CA,
USA). In all, 10mg of RNA was treated with DNAse (DNA-free,
Ambion, Austin, TX, USA), and ﬁrst strand complementary
DNA was synthesized from 2mg of the DNase-treated RNA
using the Superscript III RNase H Reverse Transcriptase kit
(Invitrogen), with Oligo-(dT) primers (Invitrogen). Mouse c-
Fos and egr-1 complementary DNA was ampliﬁed using
Power SYBR Green PCR master mix (Applied Biosystems,
Invitrogen, Carlsbad, CA, USA) in the 7500 Real-time PCR
System (Applied Biosystems). The relative amount of c-Fos
or egr-1-speciﬁc mRNA was determined by normalizing with
b-actin mRNA present in the same samples and is expressed
as fold above the saline-treated littermate WT, heterozygous
(HET) or Cav-1 KO samples. The following gene-speciﬁc
primers were used in PCR—mouse C-Fos: sense 50-CAA
CACACAGGACTTTTGCG-30, anti-sense 50-GGAGATAGCT
GCTCTACTTTG-30; mouse b-actin: sense 50-TGTTACCAA
CTGGGACGACA-30; anti-sense 50-CTGGGTCATCTTTTCA
CGGT-30. Mouse egr-1: sense 50-TCCTCTCCATCACATG
CCTG-30; anti-sense 50-CACTCTGACACATGCTCCAG-30.
Statistical comparisons of the means±s.e.m. of the trans-
cript levels were analyzed using Graphpad Prism 5.0 using a
one-way analysis of variance followed by Newman–Keuls
multiple comparison test.
Results
Cav-1 KO mice exhibit increased sensitivity to the
behavioral effects of the psychotomimetic PCP. PCP is
a psychotomimetic NMDA glutamate receptor anta-
gonist and PCP administration models in rodents various
behavioral disruptions similar to those seen in humans with
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17,18 Additionally, in non-psychotic individuals,
PCP induces psychosis, cognitive disruptions and negative
symptoms similar to those observed in schizophrenia thus
providing evidence for the NMDA hypofunction hypothesis
of schizophrenia.
19 Notably, administration of PCP or its
analog ketamine to individuals with schizophrenia greatly
exacerbates preexisting symptoms.
20,21 Accordingly, we
investigated the effects of PCP in WT and Cav-1 KO mice.
Cav-1 KO mice were generated previously by targeted
disruption of exons 1 and 2 in the CAV1 gene by insertion of
a neomycin cassette using homologous recombination
22
thereby recapitulating the insertional deletion observed as
a rare variant in schizophrenia.
PCPdisruptionofPPIisawell-establishedpharmacological
approachto model the disrupted sensory motor gating seen in
schizophrenia and related disorders.
18,23 Cav-1 KO mice
exhibited an enhanced response to PCP compared with WT
mice (Figure 1a). At all prepulse levels tested, 4mgkg
 1 PCP
signiﬁcantly disrupted PPI in Cav-1 KO mice but not in WT
mice. At a higher dose of 6mgkg
 1, PCP signiﬁcantly
disrupted PPI in both genotypes. PCP disrupted PPI in Cav-
1 KO mice to a larger extent than in WT mice, particularly at
the 4 and 8dB prepulse levels. In behavioral phenotyping
control studies, WT and Cav-1 KO mice exhibited similar
startle intensities to all auditory stimuli tested (Supplementary
Figure S1a) and no signiﬁcant difference in baseline PPI was
determined between genotypes (Supplementary Figure S1b).
Next, we examined the effect of PCP on mouse locomotor
activity in the open ﬁeld locomotion test. Before drug
administrationmicewereacclimatedtothenovelenvironment
for 30min; the novelty-induced locomotion during this initial
30-min period was similar in WT and Cav-1 KO mice
(Figure 1b). Similar results were observed when mice were
examined for novelty-induced locomotion over a 60-min
period (Supplementary Figures S1c and d). Strikingly,
administration of 4mgkg
 1 PCP signiﬁcantly increased
locomotor activity in Cav-1 KO mice in comparison with WT
mice (Figures 1b and c). In dose response studies, Cav-1 KO
mice displayed increased total distance traveled in response
to 4 and 6mgkg
 1 PCP compared with WT mice. In addition,
we also discovered that Cav-1 KO mice showed an increased
numberofstereotypicepisodesinresponsetoPCPcompared
with WT mice (Figures 1d and e). In the PCP dose response
studies, the stereotypy counts (measured as repetitive beam
breaks) in response to 4 and 6mgkg
 1 PCP was signiﬁcantly
increased in Cav-1 KO mice. Collectively, these ﬁndings
indicate genetic loss of Cav-1 sensitizes mice to the effects of
PCP in a manner reminiscent of the enhanced sensitivity
individuals with schizophrenia display to PCP’s psychotomi-
metic actions.
CAV1 KO mice show reduced sensitivity to atypical but
not typical antipsychotic drugs. Cav-1 is a scaffold for
both D2-dopamine and 5-HT2A serotonin receptors—both of
which represent canonical targets for typical (for example,
D2) and most atypical (for example, 5-HT2A and D2)
antipsychotic drugs.
14,24–26 Therefore, we assessed
antipsychotic drug activity in WT and Cav-1 KO littermate
mice. As can be seen in Figure 2a, clozapine normalized the
PCP-induced disruption of PPI in WT mice at all prepulse
levels and doses tested. In contrast, clozapine was
ineffective at normalizing PCP disrupted PPI in Cav-1 KO
mice at the 4 and 8dB prepulse levels. To further conﬁrm this
phenomenon of attenuated atypical antipsychotic activity,
mice were also administered the structurally related drug
olanzapine. As observed with clozapine, olanzapine was also
ineffective at normalizing PCP disrupted PPI in Cav-1 KO
mice (Supplementary Figure S2). To determine if this altered
antipsychotic activity in Cav-1 KO mice is due to altered
serotonin signaling, mice were administered the 5-HT2A-
selective antagonist M100907, which is known to reverse
PCP-induced disruption of PPI.
15 Importantly, M100907 was
also ineffective at normalizing PCP disrupted PPI in Cav-1
KO mice, particularly at the 4 and 8dB prepulse levels
(Figure 2b). The observation that M100907 is ineffective in
Cav-1 KO mice suggests antagonism of 5-HT2A receptors is
ineffective in these mice; ineffective 5-HT2A antagonism
because of loss of Cav-1 also likely explains the ineffec-
tiveness of clozapine and olanzapine in this behavioral index
of atypical antipsychotic drug action.
In a complementary behavioral assessment, we examined
the effects of these medications to normalize PCP-induced
hyperlocomotion. WT and Cav-1 KO mice were administered
vehicle followed by PCP, clozapine followed by PCP, or
haloperidol followed by PCP and locomotor activity was
measured. Clozapine signiﬁcantly decreased PCP-induced
locomotionandtotaldistancetraveledinWTbutnotCav-1KO
mice(Figures2candd),furtherindicatingclozapineefﬁcacyis
decreased in Cav-1 KO mice.
Interestingly, the D2-dopamine receptor antagonist and
typical antipsychotic haloperidol was equally effective in
both genotypes and signiﬁcantly decreased PCP-induced
locomotion (Figures 2c and d). This effectiveness of haloper-
idol in both genotypes indicates antagonism of D2-dopamine
receptors is preserved in Cav-1 KO mice. This also suggests
the attenuated clozapine and olanzapine effects observed
in Cav-1 KO mice are not due to alterations in D2 receptor
antagonist actions. Antagonism of 5-HT2A receptors by
M100907 provided additional insights. WT and Cav-1 mice
were administered vehicle or M100907 followed by PCP and
locomotor activity was determined as before. M100907
signiﬁcantly decreased PCP-induced locomotion in WT and
Cav-1KOmice;however,M100907waslesseffectiveinCav-1
KOmicecomparedwithWTmice(Figures2eandf).Together,
these results indicate genetic deletion of Cav-1 attenuates
atypical antipsychotic and 5-HT2A antagonist efﬁcacy and
that Cav-1 is required for the actions of these drugs to
normalize the psychotomimetic-like effects of PCP in mice.
Mouse behavioral and biochemical responses to 5-HT2A
receptors are attenuated by genetic deletion of
CAV1. The observation that both atypical antipsychotic
drugs and 5-HT2A receptor inverse agonists are ineffective
in Cav-1 KO mice prompted us to examine 5-HT2A agonist
related behaviors and signaling responses. One reliable and
extensively validated behavioral readout for 5-HT2A agonism
is the head twitch response.
16,27,28 Thus, littermate WT and
Cav-1 KO mice were administered 1.25mgkg
 1 DOI and
head twitches scored over a 35-min period; DOI-induced
head twitches were attenuated in Cav-1 KO mice at all-time
Schizophrenia risk gene CAV1
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(Figure 3b), total mouse head twitches were attenuated in
Cav-1 KO mice at concentrations above 1.0mgkg
 1, further
indicating that genetic loss of Cav-1 attenuates agonist
activity at 5-HT2A receptors.
125I-DOI receptor autoradio-
graphy (Supplementary Figure S3) and radioligand binding
(Supplementary Figure S4) in frontal cortex revealed no
difference in 5-HT2A receptor-binding sites between the
Figure 1 Genetic deletion of caveolin-1 (Cav-1) sensitizes mice to the behavioral effects of the psychotomimetic phencyclidine (PCP). (a) Cav-1 knockout (KO) mice
exhibit increased sensitivity to PCP disruption of sensory motor gaiting. Littermate wild-type (WT) and Cav-1 KO mice were injected with saline, 4 or 6mgkg
 1 PCP and
immediatelyplacedintoacousticstartleresponsechambers.Inall,6mgkg
 1PCPsigniﬁcantlydecreased(disrupted)prepulseinhibition(PPI)atallprepulselevelsinWTand
Cav-1KOmice.However,alowerdoseof4mgkg
 1PCPsigniﬁcantlydisruptedPPIinonlyCav-1KObutnotWTmice(mean±s.e.m.,n¼8to12 littermatepairs;*Po0.05
versus WT saline or Cav-1 KO saline at each prepulse level). (b, c) PCP-induced hyperlocomotion is increased in Cav-1 KO mice. Littermate WT and Cav-1 KO mice were
placedintoopenﬁeldlocomotionchambersandallowedtoacclimate;30minlatermicewereinjectedwithPCPandthetotaldistancetraveled(cm)wasdetermined.Cav-1KO
mice exhibited a greater sensitivity to 4mgkg
 1 PCP than WT mice (panel b, mean±s.e.m., n¼9 littermate pairs; *Po0.05 versus WT mice at time indicated). Cav-1 KO
mice also displayed increased total distance traveled in response to 4 and 6mgkg
 1 PCP compared with WT mice (panel c, mean±s.e.m., n¼8 to 12 littermate pairs;
*Po0.05versusWTmiceineachgroup).(d,e)StereotypymovementisincreasedinCav-1KOmiceinresponseto4mgkg
 1PCP(paneld,mean±s.e.m.,n¼9littermate
pairs).Cav-1KOmicedisplayedincreasedtotalstereotypycountsinresponseto4and6mgkg
 1PCPcomparedwithWTmice(panele,mean±s.e.m.,n¼8to12littermate
pairs; *Po0.05 versus WT mice in each group).
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Translational PsychiatryFigure 2 Caveolin-1 (Cav-1) knockout (KO) attenuates atypical antipsychotic and 5-HT2A antagonist drug actions in the phencyclidine (PCP) mouse model of psychosis.
(a, b) Cav-1 KO renders clozapine and M100907 less effective at normalizing disrupted sensory motor gaiting. Littermate wild-type (WT) and Cav-1 KO mice received
injectionsofvehicle,vehicle þ6mgkg
 1PCP,clozapine(0.5or1.0mgkg
 1) þPCPorM100907(0.5or1.0mgkg
 1) þ PCPfollowedbymeasurementofacousticstartle
responses. 6mgkg
 1 PCP signiﬁcantly decreased (disrupted) prepulse inhibition (PPI) in both genotypes at all prepulse levels. Clozapine normalized the disrupted PPI to
nearvehiclelevelsin WTmice;however,clozapinewasineffectiveatnormalizingPCPdisruptedPPI inCav-1KO miceat 4 and8dBprepulselevels (panela, mean±s.e.m.,
n¼12 littermate pairs; *Po0.05 versus vehicle-treated WT or vehicle-treated Cav-1 KO mice). Similarly, M100907 normalized the disrupted PPI to near vehicle levels in WT
mice but this was prevented in Cav-1 KO mice at 4 and 8dB prepulse levels (panel b, mean±s.e.m., n¼10 littermate pairs, *Po0.05 versus vehicle-treated WT or vehicle-
treated Cav-1 KO mice). (c–f) Clozapine and M100907, but not haloperidol, are less effective at normalizing PCP-induced hyperlocomotion in Cav-1 KO mice. Clozapine
treatments signiﬁcantly decreased the total distance traveled after PCP in WT but not Cav-1 KO mice; however, haloperidol was equally effective in both genotypes
(panels c and d, mean±s.e.m., n¼8 littermate pairs; *Po0.05 versus vehicle WT mice or vehicle Cav-1 KO mice). M100907 was also less effective at normalizing
PCP-induced hyperlocomotion in Cav-1 KO mice compared with the drug activity in WT animals (panels e and f; mean±s.e.m., n¼8 littermate pairs; *Po0.05 versus
WT 0.1 M100 þ PCP;
#Po0.05 versus WT M100 þ PCP).
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antipsychotic drug action as well as the behavioral
responses to DOI are seen in Cav-1 KO mice, these are
not due to detectable changes in the overall number of
cortical 5-HT2A receptors, but rather could be due to a
decrement in the signaling function of the receptors.
Given the aforementioned ﬁndings, we next determined
whether Cav-1 might directly modulate 5-HT2A signaling.
5-HT2A agonists such as DOI are known to selectively induce
the expression of the immediate early response genes c-Fos
and egr-1 in the mouse cortex.
16,29 In WT animals, DOI
signiﬁcantly increased cortical c-Fos and egr-1 mRNA
expression. Notably, DOI-treated Cav-1 KO mice exhibited
no signiﬁcant induction of c-Fos or egr-1, indicating genetic
loss of Cav-1 attenuates signaling activity at 5-HT2A receptors
in the mouse cortex in vivo (Figures 4a and b). In comparison,
animals heterozygous for the Cav-1 gene exhibited a reduced
c-Fos induction in response to DOI, suggesting a gene
dosage effect. As 5-HT2A receptors couple principally to Gaq
and on ligand activation, signal via the Gaq/phospholipase
Cb/IP3 pathway to mobilize calcium release from intracellular
stores, we tested if Cav-1 altered 5-HT2A-induced calcium
signaling in primary cortical neurons isolated from WT and
Cav-1 KO embryonic mice. As previously detailed,
30 DOI
does not elicit a detectable calcium response in primary
neurons probably due to a low expression of endogenous
5-HT2A receptors; however, WT neurons expressing virally
transduced 5-HT2A receptors exhibit a robust increase in
intracellular calcium dye ﬂuorescence after addition of DOI
(Figure 4c). By contrast, Cav-1 KO neurons normalized for
expression of equivalent 5-HT2A receptor levels show
attenuated responses. Quantiﬁcation of ﬂuorescence in
individual cells determined the peak calcium response after
DOI (Emax) as well as the total calcium response (area under
curve) was signiﬁcantly decreased by Cav-1 KO (Figure 4d)
(WT cells peak calcium Emax¼0.72±0.04, Cav-1 KO cells
peak calcium Emax¼0.57±0.4*; WT cells total calcium
response¼36.7±1.2, Cav-1 KO cells total calcium re-
sponse¼24.9±1.6*; *Po0.05 versus WT cells). Taken
together, these results indicate genetic loss of Cav-1
attenuates neuronal 5-HT2A signaling in vitro and in vivo.
Discussion
The major ﬁnding of this study is that genetic deletion of
CAV1—a rare structural variant associated with schizophre-
nia—leads to an enhanced susceptibility to the psychotomi-
metic actions of PCP and reduced sensitivity to atypical but
Figure 3 Mouse behavioral responses to the 5-HT2A agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) are attenuated by genetic deletion of caveolin-1 (Cav-1).
(a) Mouse head twitch responses to the 5-HT2A agonist DOI are decreased by Cav-1 knockout (KO). Littermate wild-type (WT) and Cav-1 KO mice were injected with
1.25mgkg
 1 DOI and head twitches scored over a 35-min period; DOI-induced head twitches were attenuated in Cav-1 KO mice at all-time points (panel a, mean±s.e.m.,
n¼12 littermate pairs; *Po0.05 versus WT mice). (b) Dose responsesof DOI on total mouse head twitches over a 35-min period are shown; head twitches were attenuated
in Cav-1 KO mice only at higher concentrations (panel b, mean±s.e.m., n¼6 to 8 littermate pairs; *Po0.05 versus WT mice at each concentration). (c) DOI disruption
of sensory motor gaiting in mice is prevented by Cav-1 KO. Littermate WT and Cav-1 KO mice were injected with saline, 1 or 5mgkg
 1 DOI and 10min later placed into
acousticstartleresponsechamberstoassessprepulseinhibition(PPI).DOIsigniﬁcantlydecreased(disrupted)PPIat4and8dBprepulselevelsinWTbutnotCav-1KOmice
(panel c, mean±s.e.m., n¼8 littermate pairs; *Po0.05 versus WT saline-treated mice at each prepulse level). NS, nonsigniﬁcant.
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ﬁrst in vivo evidence that the scaffolding protein Cav-1
inﬂuences both central nervous system receptor function
and psychoactive drug activity.
Scaffolding-related control mechanisms are now clearly
important for the function of many receptors and ion channels
and scaffolding proteins in general have been implicated
in schizophrenia as well as many other neuropsychiatric
diseases.
31–33 Thus, for example, in the 22q11.2 microdele-
tions arising in DiGeorge syndrome, which results in cognitive
deﬁcits and a high risk of developing schizophrenia, the
protein ZDHHC8 has been identiﬁed as a palmitoyltrans-
ferase for PSD95 that controls PSD95 function and its ability to
scaffold proteins in the postsynaptic density.
34 Genetic dele-
tion of ZDHHC8 in DiGeorge syndrome may therefore disrupt
synapticglutamatergicandGprotein-coupledreceptor(GPCR)
scaffolding with PSD95 and dysregulate receptor functions
contributing to pathologies associated with schizophrenia.
16
Here,weshowthatdisruptionsofCav-1,animportantneuronal
signaling scaffold, may contribute to the mechanisms causing
schizophrenia and possibly other neuropsychiatric disorders.
Our identiﬁcation here of Cav-1-mediated regulation of
5-HT2A receptors raises the intriguing possibility for altered
5-HT2A receptor function inindividuals with schizophrenia that
possess the CAV1 mutation. The observation that Cav-1 KO
mice exhibit increased sensitivity to the psychotomimetic
effects of PCP (Figure 1), a phenomenon also observed in
humans with schizophrenia,
20,21 is a compelling behavioral
observation bridging the mouse model and human schizo-
phrenia. The mechanisms underlying this enhanced PCP
sensitivity in Cav-1 KO mice are unknown, although our
ﬁndings implicate dysfunctional serotonergic signaling.
Recent studies have also indicated altered mGluR function
in Cav-1 KO mice as well as alterations in synaptic
plasticity.
11,35 NMDA receptors are not currently known
to directly interact with caveolins, but both proteins do
colocalize in hippocampal neurons where Cav-1 is required
for NMDA receptor signaling.
36 However, hippocampal
NMDA-mediated long-term depression is not altered in
Cav-1 KO mice, although the mGluR-mediated long-term
depression is altered.
35 Therefore, this enhanced response to
PCP observed in Cav-1 KO mice may involve changes in
Figure 4 5-HT2A signaling responses to the agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) are attenuated in vivo and in vitro by genetic deletion of caveolin-1. (a, b)
Littermate wild-type (WT) and caveolin-1 (Cav-1) knockout (KO) mice were injected with 1.0mgkg
 1 DOI, 1h later frontal cortex was isolated, mRNA extracted and transcript
levels of c-Fos and egr-1 determined by real-time PCR. DOI-induced c-Fos and egr-1 gene expression in frontal cortex was decreased in mice heterozygous for Cav-1; DOI-
induced gene expression wasprevented inKO mice (panels a andb, mean±s.e.m.,n¼5 littermatemice for eachgroup; *Po0.05 versussaline-treatedmice in each group).
(c) Neuronal 5-HT2A receptor calcium signaling is decreased by genetic deletion of Cav-1. Primary cortical neurons were isolated from WT and Cav-1 KO mice and cultured in
96-well plates.Neurons were infectedwith lentivirusesencoding 5-HT2A receptorsandintracellular calcium release wasdeterminedby ﬂuorescence calciumdye imagingusing
high-content imaging microscopy. Images of cells are shown before (left panels) and after (middle panels) an automated addition of the 5-HT2A agonist DOI.
WTneuronsexpressing5-HT2Areceptors(middlepanels)exhibitedarobustincreaseinintracellularcalciumdyeﬂuorescenceafterDOI.Incomparison,KOneuronsexpressing
5-HT2Areceptors(lowerpanels)displayedareducedintracellularcalciumdyeﬂuorescenceafteragonist.Thecalciumdyeﬂuorescenceinindividualrespondingcellsinthewells
(segmenting)wasdetermined.(d)Quantiﬁcationofcalcium dyeﬂuorescenceinindividualcellsisshown andexpressedasfoldoverinitial ﬂuorescence;KOneuronsexhibiteda
reduced peak and total calcium response (Figure 4d, mean ﬂuorescence intensity±s.e.m. from 490 cells per group from n¼3 cell preparations).
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receptor scaffolding/trafﬁcking by lack of Cav-1, both possi-
bilities warrant future study.
Caveolins are thought to regulate GPCR signaling cas-
cades by two distinct mechanisms (1) Caveolin scaffolding
of GPCRs, G proteins and their associated effectors in
membrane microdomains to regulate protein–protein interac-
tions and therefore signal transduction and, (2) caveolin
regulation of receptor trafﬁcking as caveolins can control a
distinct form of clathrin-independent endocytosis.
9,10 How-
ever, exactly how caveolins function in the central nervous
system remains unclear, although recent evidence indicates
Cav-1 controls constitutive receptor endocytosis in hippo-
campalneuronsforsomeGPCRssuchasthemGluR1/5
11and
signaling by hippocampal mGluR1/5 receptors to control
hippocampal long-term depression is abnormal in Cav-1 KO
mice.
35This isparticularlyinteresting asboth mGluR1/5and5-
HT2A receptors couple primarily through Gaq mechanisms,
suggesting multiple GPCR-Gaq signaling cascades may
require Cav-1. Consistent with this notion, in our previous
investigations, we determined that Cav-1 and Cav-2 interact
with 5-HT2A receptors and stable knockdown of caveolins
profoundly inhibits Gaq-mediated calcium signaling.
14 We
also previously determined that the Cav/5-HT2A interaction
promotes a complex between Gaq and the receptor and this
may be a mechanism by which caveolin inﬂuences 5-HT2A
receptor signaling and pharmacology.
Cav-1 scaffolding also seems essential for the salutary
actions of atypical antipsychotic drugs in mice. Using the
PCP mouse model of psychosis, we determined that genetic
loss of Cav-1 attenuated the ability of the atypical antipsycho-
tics clozapine and olanzapine to normalize the PCP-disrupted
PPI and the PCP-induced hyperlocomotion (Figure 2). Cav-1
KO similarly attenuated the activity of the selective 5-HT2A
antagonist M100907 in both behavioral tests. However, the
typical antipsychotic haloperidol, which acts primarily as a
D2-dopaminereceptorantagonist,wasequallyeffectiveinWT
andCav-1KOmice.Inaddition,theincreasedpotencyofPCP
in Cav-1 KO mice (Figure 1) cannot thoroughly explain the
reduced efﬁcacy of these atypical antagonists in behavioral
studies. This is because the relative difference in PCP alone
effects between WT and Cav-1 KO mice is not proportional to
those differences observed between WT and Cav-1 KO mice
after treatment with PCP and antipsychotics (Figure 2).These
results indicate atypical antipsychotics, acting via antagonism
at 5-HT2A and other receptors, require the expression of
Cav-1 for their full efﬁcacy in mice. As total receptor number is
unchanged by Cav-1 KO, this requirement for Cav-1 could be
explained by an attenuated 5-HT2A receptor signaling. We
recently determined that the presynaptic component of the
serotonergic neuronal system is required for clozapine’s
antipsychotic activity (that is, normal 5-HT2A signaling via
serotonin must be intact for effective antagonism by clozapine
in these PCP behavioral studies).
15 Therefore, the reduced
5-HT2AsignalingevidentinCav-1KOmousecortex(Figure4a)
in cultured cortical neurons (Figure 4b) and in behavioral
responses (Figure 3) is an indication that receptor activity
is also reduced; this could make antagonism of the recep-
tors less effective. Also consistent with this notion, we
recently determined that PSD95 KO mice exhibit reduced
agonist-induced 5-HT2A signaling, which is associated with
decreased clozapine activity in the KO mice.
16 The ﬁndings
here that Cav-1 is required for antipsychotic activity, along
with our recent PSD95 KO mice results, indicate that 5-HT2A
signaling via scaffolding proteins appears to be a requirement
for atypical antipsychotic activity in mouse models.
In summary, we have found that Cav-1 KO mice are
supersensitive to the psychotomimetic actions of PCP. We
also discovered that genetic loss of CAV1 attenuates the
biochemical and behavioral actions of atypical antipsychotic
drugs and that 5-HT2A agonists and inverse agonists in vitro
and in vivo have attenuated effects in Cav-1 KO mice. These
ﬁndings provide fresh insights into the roles of caveolin in the
central nervous system and provide support for the involve-
ment of caveolin in the etiology of schizophrenia. Given that
Cav-1 KO mice show resistance to the apparent antipsychotic
actions of clozapine and olanzapine, it appears that caveolin
is also required for atypical antipsychotic drug actions.
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